Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative

Author:

Wyse Richard K.1,Isaacs Tom1,Barker Roger A.2,Cookson Mark R.3,Dawson Ted M.4,Devos David5,Dexter David T.6,Duffen Joy1,Federoff Howard7,Fiske Brian8,Foltynie Thomas9,Fox Susan10,Greenamyre J. Timothy11,Kieburtz Karl12,Kordower Jeffrey H.13,Krainc Dimitri14,Matthews Helen1,Moore Darren J.15,Mursaleen Leah1,Schwarzschild Michael A.16,Stott Simon R.W.1,Sulzer David17,Svenningsson Per18,Tanner Caroline M.19,Carroll Camille20,Simon David K.21,Brundin Patrik22

Affiliation:

1. Cure Parkinson’s, London, UK

2. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

3. Cell Biology and Gene Expression Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

4. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA

5. Department of Medical Pharmacology and Neurology, University of Lille, CHU Lille, Lille Neurosciences and Cognition Inserm UMR-S-U1172, Lille, France

6. Parkinson’s UK, London, UK

7. Henry and Susan Samueli College of Health Sciences, University of California, Irvine CA, USA

8. Research Programs, The Michael J. Fox Foundation for Parkinson’s Research, New York, NY, USA

9. Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK

10. Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, ON, Canada

11. Department of Neurology, Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA, USA

12. Department of Neurology Center for Health and Technology, University of Rochester, Rochester, NY, USA

13. ASU-Banner Neurodegenerative Disease Research Center and School of Life Sciences, Arizona State University, Tempe, AZ, USA

14. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

15. Van Andel Institute, Grand Rapids, MI, USA

16. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

17. Department of Neurology, Columbia University, New York, NY, USA

18. Karolinska Institute, Stockholm, Sweden

19. Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA

20. Translational and Clinical Research Institute, Newcastle University, Newcastle, UK

21. Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

22. Neuroscience and Rare Diseases, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

Abstract

In 2011, the UK medical research charity Cure Parkinson’s set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson’s disease (PD). The first committee meeting was held at the Van Andel Institute in Grand Rapids, Michigan in 2012. This group of PD experts has subsequently met annually to assess and prioritize agents that may slow the progression of this neurodegenerative condition, using a systematic approach based on preclinical, epidemiological and, where possible, clinical data. Over the last 12 years, 171 unique agents have been evaluated by the iLCT committee, and there have been 21 completed clinical studies and 20 ongoing trials associated with the initiative. In this review, we briefly outline the iLCT process as well as the clinical development and outcomes of some of the top prioritized agents. We also discuss a few of the lessons that have been learnt, and we conclude with a perspective on what the next decade may bring, including the introduction of multi-arm, multi-stage clinical trial platforms and the possibility of combination therapies for PD.

Publisher

IOS Press

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3